📊 CRVS Key Takeaways
Is Corvus Pharmaceuticals, Inc. (CRVS) a Good Investment?
Corvus Pharmaceuticals is a pre-revenue development-stage biopharmaceutical company burning approximately $10.4M annually in operating cash flow with no commercial revenue generation. While the balance sheet is fortress-like with $240.7M equity, zero debt, and $40.1M cash reserves providing 3-4 years of runway, the company remains entirely dependent on unproven pipeline success with no clear path to profitability in the near term.
Corvus Pharmaceuticals shows the classic profile of a pre-revenue biotech with weak operating economics: no reported revenue, a $42.97M operating loss, and deeply negative free cash flow. The balance sheet is currently clean with no meaningful debt and strong reported liquidity ratios, but the very low cash balance relative to annual cash burn raises material funding risk unless additional capital or non-cash current assets support near-term operations.
Corvus Pharmaceuticals, Inc. Key Strengths (CRVS)
- Fortress balance sheet: $240.7M stockholders' equity with only $12.5M liabilities and zero debt
- Strong liquidity position: 19.81x current ratio and $40.1M cash provides multi-year funding runway
- Improved loss trajectory: Diluted EPS improved 48% YoY despite ongoing losses, suggesting operational efficiency gains
- Debt-free balance sheet with low total liabilities relative to equity
- Strong reported current and quick ratios indicate near-term balance sheet flexibility
- EPS loss improved year over year, suggesting some reduction in per-share loss pressure
CRVS Stock Risks: Corvus Pharmaceuticals, Inc. Investment Risks
- Zero revenue: Pre-commercial stage creates complete dependence on pipeline success with no diversification
- Persistent cash burn: $10.4M annual operating losses with negative free cash flow limits window for clinical success
- Development risk: No visibility into pipeline viability, clinical trial success rates, regulatory approval likelihood, or commercialization timeline
- No reported revenue means the business is not yet demonstrating commercial traction
- Large operating and free cash flow losses indicate continued dependence on external funding
- Cash and equivalents of $4.58M appear very low versus operating cash burn of $32.80M
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining cash runway extension
- Pipeline clinical trial milestones and FDA regulatory progress
- Operating expense trends and R&D spending allocation efficiency
- Quarterly operating cash burn versus cash and equivalents
- Any transition from pre-revenue status to sustainable collaboration or product revenue
Corvus Pharmaceuticals, Inc. (CRVS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 19.81x current ratio provides a solid financial cushion.
CRVS Profit Margin, ROE & Profitability Analysis
CRVS vs Healthcare Sector: How Corvus Pharmaceuticals, Inc. Compares
How Corvus Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Corvus Pharmaceuticals, Inc. Stock Overvalued? CRVS Valuation Analysis 2026
Based on fundamental analysis, Corvus Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Corvus Pharmaceuticals, Inc. Balance Sheet: CRVS Debt, Cash & Liquidity
CRVS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Corvus Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.56 indicates the company is currently unprofitable.
CRVS Revenue Growth, EPS Growth & YoY Performance
Corvus Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
CRVS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Corvus Pharmaceuticals, Inc. (CIK: 0001626971)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRVS
What is the AI rating for CRVS?
Corvus Pharmaceuticals, Inc. (CRVS) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRVS's key strengths?
Claude: Fortress balance sheet: $240.7M stockholders' equity with only $12.5M liabilities and zero debt. Strong liquidity position: 19.81x current ratio and $40.1M cash provides multi-year funding runway. ChatGPT: Debt-free balance sheet with low total liabilities relative to equity. Strong reported current and quick ratios indicate near-term balance sheet flexibility.
What are the risks of investing in CRVS?
Claude: Zero revenue: Pre-commercial stage creates complete dependence on pipeline success with no diversification. Persistent cash burn: $10.4M annual operating losses with negative free cash flow limits window for clinical success. ChatGPT: No reported revenue means the business is not yet demonstrating commercial traction. Large operating and free cash flow losses indicate continued dependence on external funding.
What is CRVS's revenue and growth?
Corvus Pharmaceuticals, Inc. reported revenue of N/A.
Does CRVS pay dividends?
Corvus Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CRVS SEC filings?
Official SEC filings for Corvus Pharmaceuticals, Inc. (CIK: 0001626971) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRVS's EPS?
Corvus Pharmaceuticals, Inc. has a diluted EPS of $-0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CRVS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Corvus Pharmaceuticals, Inc. has a C grade with 80% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CRVS stock overvalued or undervalued?
Valuation metrics for CRVS: ROE of -5.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CRVS's AI grade for 2026?
Our dual AI analysis gives Corvus Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRVS's free cash flow?
Corvus Pharmaceuticals, Inc.'s operating cash flow is $-10.4M, with capital expenditures of $91.0K.
How does CRVS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -5.7% (avg: 15%), current ratio 19.81 (avg: 2).